Renaissance Technologies’s Lucid Diagnostics LUCD Stock Holding History

Renaissance Technologies’s Portfolio LUCD Stock Details LUCD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$575K	Sell	499,661 -326,866	-40%	-$416K	﹤0.01%	2545
2025 Q4	$901K	Buy	826,527 +532,894	+181%	+$596K	﹤0.01%	2338
2025 Q3	$297K	Buy	293,633 +50,354	+21%	+$55K	﹤0.01%	3003
2025 Q2	$280K	Sell	243,279 -215,786	-47%	-$279K	﹤0.01%	3065
2025 Q1	$684K	Buy	+459,065	New	+$551K	﹤0.01%	2611
2022 Q1	–	Sell	-20,000	Closed	-$107K	–	4315
2021 Q4	$107K	Buy	+20,000	New	+$162K	﹤0.01%	3668

Other funds holding LUCD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

MCM

Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

Renaissance Technologies's LUCD Position: Q1 2026 in Review

Renaissance Technologies reduced its Lucid Diagnostics (LUCD) stake by 40% in Q1 2026, selling an estimated $416K and leaving 499,661 shares worth $575K. The position accounts for ﹤0.01% of the portfolio, ranked #2545.

Renaissance Technologies first reported a position in LUCD in Q4 2021 and has held it in 6 quarters since. The position peaked at $901K in Q4 2025. 103 funds tracked by Wall St. Rank hold LUCD as of Q1 2026.

Renaissance Technologies held 499,661 shares of Lucid Diagnostics worth $575K as of Q1 2026.
Renaissance Technologies sold 326,866 Lucid Diagnostics shares in Q1 2026, an estimated $416K.
Lucid Diagnostics made up ﹤0.01% of Renaissance Technologies's portfolio in Q1 2026, its #2545 holding.
Renaissance Technologies first reported a position in Lucid Diagnostics in Q4 2021 and has held it in 6 quarters since.
Renaissance Technologies's Lucid Diagnostics position peaked at $901K in Q4 2025.
103 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.